Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr378.70 DKK
Change Today +5.70 / 1.53%
Volume 5.3M
As of 11:04 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Novo Allé

Bagsvaerd, 2880

Denmark

Phone: 45 44 44 88 88

Fax: 45 44 49 05 55

Novo Nordisk A/S, a healthcare company, engages in discovering, developing, manufacturing, and marketing pharmaceutical products and services. The company markets its products in approximately 180 countries. Segments The company operates through two business segments, Diabetes Care and Biopharmaceuticals. Diabetes Care This segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs, and obesity. In December 2014, the GLP-1 agonist liraglutide was approved in the United States in a 3 mg dose for weight management. The trade name for this product would be Saxenda and launch is planned for the first half of 2015. Biopharmaceuticals This segment covers the therapy areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Customers The company conducts business with customers in Iran, including the Government of Iran (GOI). In 2014, the company sold its products and devices directly to two GOI-controlled pharmaceutical companies (Exir Pharmaceutical Co. (Exir) and Darou Pakhsh Trade Development Co.) and contracted with two GOI-controlled pharmaceutical manufacturers to fill, formulate, and/or re-pack the company’s certain products (Exir and Darou Pakhsh Pharma. Chem. Co.). Novo Nordisk Pars, a wholly-owned affiliate of the company located in Iran contracts with four GOI-controlled companies (Exir; Darou Pakhsh Trading Co.; Darou Pakhsh Co.; and Hedjat Distribution Co.) to import and distribute its products. NNE Pharmaplan A/S, a wholly-owned affiliate of the company, has a contract with the Iranian Blood Research & Fractionation Company for the engineering, procurement, and construction of a human plasma fractionation plant in Iran for the production of human plasma derivatives. NNE Pharmaplan A/S also has a contract with SOHA Helal Iran Medical Devices Co., a GOI-controlled company, to provide raw materials for dialysis filters. Markets and Distribution The company’s insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors, and independent agents with responsibility for specific geographical areas. The primary markets are North America, China, Japan, and the major European countries. Its international operations are in Algeria, Turkey, Australia, India, Argentina, Brazil, and Russia. In addition, the company conducts business with customers in Syria, Sudan, and Cuba. Patents The company’s major delivery devices are protected by various patents of which the first would expire in January 2019. The company holds a formulation patent on NovoLog/NovoRapid, which provides coverage until June 2017 in all major markets. In addition, the company holds a formulation patent on NovoLog Mix/NovoMix in the United States, which provides coverage until June 2017. The company holds two formulation patents on the room temperature stable preparation of NovoSeven, which provides coverage of this formulation until 2023 and 2024, respectively, in all major markets. The expiry of the drug compound patent has had limited impact on the sale of NovoSeven due to the complexity relating to the regulatory pathways for ‘biosimilar’ coagulation factors in the United States, the EU, and Japan. Norditropin is not covered by a drug compound patent. However, the formulation used is covered by a formulation patent that expires in 2017 in the United States, Europe, and Japan. History Novo Nordisk A/S was founded in 1925. The company was incorporated in 1931.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVOB:DC kr378.70 DKK +5.70

NOVOB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $64.32 USD -0.34
Actavis plc $289.74 USD +6.88
Amgen Inc $160.36 USD +2.45
Biogen Inc $386.22 USD +12.29
Bristol-Myers Squibb Co $64.66 USD +0.93
View Industry Companies
 

Industry Analysis

NOVOB

Industry Average

Valuation NOVOB Industry Range
Price/Earnings 34.6x
Price/Sales 11.0x
Price/Book 32.0x
Price/Cash Flow 27.3x
TEV/Sales 8.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO NORDISK A/S-B, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.